Ochre Bio, Boehringer Ink $1B Deal for Novel Liver Disease Treatments

Apr 22, 2024, 11:29 AM

Ochre Bio, a UK-based biotech startup and Y Combinator alum, has entered into a significant partnership with Boehringer Ingelheim, spearheaded by Boehringer's SVP/Global Head of Cardiometabolic Diseases Research, Søren Tullin, to develop novel regenerative treatments for chronic liver disease. This collaboration involves an upfront and near-term payment of $35 million, with potential future payments reaching up to $1 billion if certain milestones are achieved. Ochre Bio's approach, lauded for its genomics experience and innovative technology, includes analyzing thousands of donated human livers to better understand disease causes and exploring RNA modifications to enhance protein translation. Søren Tullin noted that Ochre Bio brings unique and exciting capabilities to the table, particularly in the application of advanced genomics and machine learning.